Pancreas cancer
Conditions
Interventions
Gemcitabine, S-1, Intensity modulated radiation therapy
Sponsors
3rd department of surgery Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically or cytlogically proven diagnosis of pancreas cancer. 2) A CT or A MRI with contrast of the thorax, abdomen and pelvis exclude distance metastases and peritoneum dissemination. 3) Zubroad performance status is 0-2. 4) Patients have not prior radiotherapy to upper abdomen. 5) Patients must provide clinical condition and have the ability to comprehend and informed consent prior to study entry.
Exclusion criteria
Exclusion criteria: 1) Patients have four months or less life expectancy. 2) Patients have severe co-morbidities disease. 3) Woman of child bearing potential, expectant or nursing woman. 4) Patients have a history of severe drug allergy. 5) Patients have synchronous active cancer. 6) Patients had distant metastases after induction chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Resection rate Tumor response rate Local recurrence rate Progression free survival Adverse event rate QOL | — |
Countries
Japan
Contacts
Public ContactYuichi Nakakawa
Tokyo Medical University 3rd department of surgery
Outcome results
None listed